Etoricoxib 60 mg + Etoricoxib 90 mg
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Injuries of the Shoulder
Conditions
Soft Tissue Injuries of the Shoulder, Tenosynovitis and Bursitis Affecting the Shoulder
Trial Timeline
Nov 1, 2009 → Dec 1, 2010
NCT ID
NCT00876317About Etoricoxib 60 mg + Etoricoxib 90 mg
Etoricoxib 60 mg + Etoricoxib 90 mg is a phase 3 stage product being developed by Merck for Soft Tissue Injuries of the Shoulder. The current trial status is terminated. This product is registered under clinical trial identifier NCT00876317. Target conditions include Soft Tissue Injuries of the Shoulder, Tenosynovitis and Bursitis Affecting the Shoulder.
What happened to similar drugs?
2 of 14 similar drugs in Soft Tissue Injuries of the Shoulder were approved
Approved (2) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00876317 | Phase 3 | Terminated |
Competing Products
20 competing products in Soft Tissue Injuries of the Shoulder